DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS

Hafsah Nabi; R. Ibsen; Michael Ibsen; Jakob Kjellberg; Merete Lund Hetland; Bente Glintborg

doi:10.1136/annrheumdis-2023-eular.812

DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS

Hafsah Nabi, R. Ibsen, Michael Ibsen, Jakob Kjellberg, Merete Lund Hetland, Bente Glintborg

Afdeling for Rygkirurgi, Led- og Bindevævssygdomme HOC

Originalsprog	Dansk
Publikationsdato	2023
DOI	https://doi.org/10.1136/annrheumdis-2023-eular.812
Status	Udgivet - 2023
Begivenhed	EULAR 2023 - Milano, Italien Varighed: 31 maj 2023 → 2 jun. 2023

Konference

Konference	EULAR 2023
Land/Område	Italien
By	Milano
Periode	31/05/2023 → 02/06/2023

Adgang til dokumentet

10.1136/annrheumdis-2023-eular.812

Citationsformater

Nabi, H., Ibsen, R., Ibsen, M., Kjellberg, J., Hetland, M. L., & Glintborg, B. (2023). DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS. Annals of the rheumatic diseases, vol. 82, suppl. 1, page 441. Abstract fra EULAR 2023, Milano, Italien. https://doi.org/10.1136/annrheumdis-2023-eular.812

DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS. / Nabi, Hafsah; Ibsen, R.; Ibsen, Michael et al.
2023. Annals of the rheumatic diseases, vol. 82, suppl. 1, page 441 Abstract fra EULAR 2023, Milano, Italien.

Publikation: Konferencebidrag › Konferenceabstrakt til konference › Forskning › peer review

Nabi, H, Ibsen, R, Ibsen, M, Kjellberg, J, Hetland, ML & Glintborg, B 2023, 'DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS', EULAR 2023, Milano, Italien, 31/05/2023 - 02/06/2023 s. Annals of the rheumatic diseases, vol. 82, suppl. 1, page 441. https://doi.org/10.1136/annrheumdis-2023-eular.812

@conference{158776df3ed84f45bd273121566cad95,

title = "DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS",

author = "Hafsah Nabi and R. Ibsen and Michael Ibsen and Jakob Kjellberg and Hetland, {Merete Lund} and Bente Glintborg",

note = "COPECARE; EULAR 2023 ; Conference date: 31-05-2023 Through 02-06-2023",

year = "2023",

doi = "10.1136/annrheumdis-2023-eular.812",

language = "Dansk",

pages = "Annals of the rheumatic diseases, vol. 82, suppl. 1, page 441",

}

TY - ABST

T1 - DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS

AU - Nabi, Hafsah

AU - Ibsen, R.

AU - Ibsen, Michael

AU - Kjellberg, Jakob

AU - Hetland, Merete Lund

AU - Glintborg, Bente

N1 - COPECARE

PY - 2023

Y1 - 2023

U2 - 10.1136/annrheumdis-2023-eular.812

DO - 10.1136/annrheumdis-2023-eular.812

M3 - Konferenceabstrakt til konference

SP - Annals of the rheumatic diseases, vol. 82, suppl. 1, page 441

T2 - EULAR 2023

Y2 - 31 May 2023 through 2 June 2023

ER -